If replicated in future studies, these collective findings might have important implications for the interpretation of changes in the CSF Aβ42/Aβ40 ratio, as well as NfL and t-tau, in response to treatment in AD clinical trials. The gene discussed is NEFL; the disease is Alzheimer disease.